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Plasmin is shown to specifically cleave vitronectin at the Arga6*-Se? bond, 18 amino acid residues upstream from the site of the endogenous 
cleavage which gives rise to the two-chain form of vitronectin in plasma. The cleavage site is established using the exclusive phosphorylation of 
Se? with protein kinase A. As a result of the plasmin cleavage, the affinity between vitronectin and the type-l inhibitor of plasminogen ac:ivatoe 
(PAI-1) is significantly reduced. This cleavage is stimulated by glycosaminoglycans, which are known to anchor vitronectin to the extracellular 
matrix. A mechanism is proposed through which plasmin can arrest its own production by feedback signalling, unleashing PAL1 from the immobi- 
lized vitronectin found in the vascular subendothelium, which becomes exposed at the locus of a hemostatic event. 
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1. INTRODUCTION 
The activation of plasminogen is known to be involv- 
ed in major physiological and pathological processes 
such as fibrinolysis and thrombolysis, inflammation, 
ovulation, tissue remodeling and development, malig- 
nant transformation and tumor cell invasion [ 1,2]. This 
activation is under the concerted control of 
plasminogen activators and their inhibitor PAI- [3,4], 
which was recently shown to be bound to vitronectin in 
the extracellular matrix [S-8]. 
Originally discovered as a serum spreading factor [9], 
vitronectin is now recognized as a multifunctional 
regulatory protein [IO] involved in a variety of ex- 
tracellular processes such as the attachment and 
spreading of normal and neoplastic cells [ll] and the 
function of the complement [l&13] and coagulation 
pathways [ 12,14, IS]. In circulating blood, vitronectin 
occurs in 2 molecular forms: a single chain 75 kDa form 
(V75) and a clipped form (VG + IO) composed of two 
chains (65 kDa and 10 kDa) which are held together by 
a disulfide bridge [12,16]. V75 was previously shown to 
be phosphorylated at Ser378 by PKA, released upon 
thrombin stimulation of platelets [ 17-211. By contrast, 
at physiological pT-I, V65 ,. r. is stoichiometrically 
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phosphorylated only in the presence or glycosamino- 
glycans [18] (heparin or heparan sulfate) which were 
shown to expose its otherwise buried Ser”” [19]. Vg5 + to 
was also shown to possess a higher affinity for heparin 
[ 15,181. The endogenous proteinase that converts V’S 
into v65 + 10 was not identified so far, but this cleavage 
was shown to occur at the Arg379-Ala380 bond [12,19]. 
Until recently it was assumed that there are ‘no major 
functional differences’ between V75 and v65 + 10 [22]. 
However, the distinctly different behaviour in their 
phosphorylation by PKA [18,19] raised the possibility 
that the V7S+V65 + 1o conversion may be physiologically 
important. We therefore set out to study this conver- 
sion. The enzymes which were reported to simulate the 
endogenous cleavage were trypsin, elastase and plasmin 
[lo]. Among these, plasmin seemed to be the most in- 
teresting from the physiological point of view. This 
paper shows that the plasmin cleavage site is actually 18 
amino acid residues upstream from the endogenous 
cleavage site, and that this plasmin cleavage has distinct 
functional consequences, attenuating the binding of 
PM-1 to vitronectin. 
2. MATERIALS AND METHODS 
2. I. Materials purchased 
Freshly-frozen human plasma was obtained from the Tel 
Hashomer Medical Center, Ramat Gan, Israel. Heparin and 
polyethylene glycol (A!,= 3350) were purchased from Sigma. Rabbit 
anti-human vitronectin polyclonal antibodies were from Calbiochem. 
Alkaline phosphatase-labeled antibodies to rabbit 1gG were obtained 
from Dako, Copenhagen. Plasmin, PAI- and rabbit anti human 
PAI- were purchased from American Diagnostica Inc., New York. 
[$‘P]ATP (3000 Ci/mmol) was obtained from Amersham. Im- 
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mobilon (PVDF) membranes were supplied by Milliporc Corp. 
Nitrocellulose paper (0.45 am) was from Schleicher and Schuell. 
2.2. Vitronectin 
Vitronectin was prepared from freshly-frozen human plasma using 
a purification procedure described elsewhere [tl]. Our preparations 
usually contained the 2 molecular forms of this protein: V~S - a one- 
chain (75 kDa) form, and V . 6~ + 10 - a protcolytically clipped, two- 
chain protein (65 kDa and 10 kDn) held together by a disuifide bridge 
[12,13]. 
2.3. The cutalytic scrbanit of PKA 
Pure catalytic subunit of PKA was prepared according 10 Beavo et 
al. 1231 and assayed as described elsewhere [24]. 
2.4. Identt~ication and assqv of vifroneclin b.v phosphorylafion r&h 
PKA 
Aliquots of the samples to be assayed were added to a reaction mix- 
ture (final volume SO/tI) which contained the following constituents 
at the indicated final concentrations: PKA (2.5 pg/m!); 
M~(CHJCOO)Z (IO mM); [y”P]ATP (IOJ~M, 50 Ci/mmol), HEPES 
(SO mM, pH 7.5). Phosphorylation was allowed to proceed for I5 min 
at 30°C and arrested by addition of 12 pl of sample buffer to yield the 
following final composition: SDS (2%); 2-mercaptoethanol (0.75 M); 
glycerol (10%); Tris-HCI buffer (25 mM, pH 6.7); bromophcnol blue 
(0.1 mg/ml). The samples were subjected to SDS-PAGE and 
autoradiography or counting. 
2.5. Procedures curried 0111 us described in Ihe lilerature 
Protein concentration was determined by the method of Bradford 
[25]. SDS-PAGE was carried out according to the procedure describ- 
ed by Laemmli [26]. The gels were fixed and stained with a Coomassie 
blue solution (0.25%) in 50% methanol and 7% acetic acid. Destain- 
ing was carried out with a 20% isopropanol solution containing acetic 
acid (7070). Gels assayed for radioactively labeled proteins were dried 
under vacuum and autoradiographed at - 20°C using Agfa X-ray 
film. Alternatively, the lanes of such gels were cut out and their 
radioactivity was counted in a scintillation counter using a toluene- 
based scintillant. Immunoblotting was carried out as described by 
Towbin et al. [27]. The binding of Vn or Vn’ to immobilized PAI-I 
was determined as described by Salonen et al. [6]. The activation of 
PAI-I by boiling was carried auf as described by Katagiri et al. [28]. 
2.6. Amino mid sequencing 
Sequence analysis of vitronectin or its fragments was performed 
after resolution by SDS-PAGE (using a 7-20% linear gradient of 
polyacrylamide) and transfer by Western blotting onto an lmtnobilon 
membrane [29] in 50 mM HEPES, pH 7.5 and 20% methanol. A con- 
stant current of 300 rnAmp was applied for 3 h with cooling. The Im- 
mobilon paper was washed extensively with distilled water, stained 
with Coomassie blue (0.25%) in 50% methanol and 7vo acetic acid 
and washed with a I: 1 mixture of methanol and 20% acetic acid to 
remove the excess dye. The stained bands of interest were cut out 
from the paper and stored desiccated at -20°C until sequencing by 
an Applied Biosystcm 475A sequencer. 
3. RESULTS AND DISCUSSION 
3.1. Identifying the plasmin cleavage site 
When plasmin is allowed to cleave a vitronectin 
preparation composed of V75 and v6C+ 10, monitoring 
the cleavage of SDS-PAGE and either protein staining 
(Fig. 1A) or immunoblotting with anti-Vn (Fig. IB), 
one may initially be led to believe that V75 is converted 
into v65 + 10, i.e. that plasmin simulates this endogenous 
cleavage [lo]. However, if the plasmin cleavage is 
monitored by PKA pl-xphorylation of the cleavage 
products with [r3*P]ATP, SDS-PAGE and 
autoradiography, it becomes clear that the plasmin 
cleavage site must be upstream from the endogenous 
A 
;pemassie 
Staining 
KDE 
Time 
min. 
il I KDa 
-/- 75 
\- 6653 
Time 
min. lllN 
0 3 51530 
6 
PKA 
Radiolabeling 
of Ser 378 
Time 
min. 
b 
Fig. I. Plasmin cleavage of vitronectin monitored (A) by protein staining; (B) by immunoreactivity; (C) by PKA radiolabeling of Scr”‘“. Panel 
A: the reaction mixtures (50~1 each) contained vitronectin (14O/cg/ml), plasmin (1 &nil) and HEPES buffer, pH 7.5 (50 mM) (all final concentra- 
tions). Cleavage wrls allowed to proceed at 37°C and arrested at the times indicated by boiling (3 rnin at 95°C) with 12~~1 of an ‘arresting buffer’ 
composed of SDS (10% w/v), 2-mcrcaptocthanol(3.75 M), glycerol (50%), Tris-HCI buffer (125 mM, pH 6.7) and Bromophenol blue (0. I mg/ml). 
The samples were then analyzed by SDS/PAGE (7-20% gels) under reducing conditions [26], then stained with Coomassie blue. Puu~/ U: ex- 
perimental details as described in panel A except for the fact that the analysis was carried out with 7% gels and immunoblotting (271 with polyclonal 
anti-human vitronectin antibodies. Punel C: tllc reaction mixtures were of 3041 (concentration as in panel A), and the cleavage was arrested by 
boiling (5 min at 95°C) only. Vitronectin phosphorylation was carried out with PKA by addition of 20~1 of a solution containing the following 
phosphorylation ingredients (final concentrations given): C subunit of PKA (25 nM), [yJ2P]ATP (50 PM, specific radioactivity 0.5 Ci/mmol), 
Mg(CH&00)2 (IO mM). Phosphorylation was allowed to proceed for 30 min, then stopped by boiling with 12~1 of the ‘arresting buffer’. After 
SDS/PAGE under reducing conditions (7-12% gels) the gels were subjected to autoradiography. Each of the experiments described above is 
representative of at least 3 experiments carried out with different preparations of vitronectin and plasmin, Note that in panel (C) both the 75 and 
65 kDa bands are labeled, since the phosphorylation is carried out on denatured (boiled) vitronectin in which Se?” is exposed [IS,191 in both V,S 
ant1 V~S+ 10. Also note that the amount of [32P]V~ seen in this panel does not represent its relative concentration in the reaction mixture. Most of 
it diffuses out of the gel during washing, since V2 is a very basic and hydrophilic peptide (cf. legend to Fig. 2, lower panel). 
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cleavage site (Arg379 -Ala3”), since the single phos- 
phorylation site (Ser378) is now found in 2 small-chain 
cleavage products (- 12 kDa and -2 kDa, Fig. 1C). 
Such products would be obtained from V75 and v65 + 10 
respectively, if the plasmin cleavage site occurs about 
twenty amino acid residues (-2 kDa) before Arg379, 
leaving the entire phosphorylation consensus sequence 
of PKA [30] (residues 375-379) in the small fragments. 
Indeed, a more careful. examination of the cleavage in 
Figs. 1A and B shows that both the V75 and the V65 + 10 
chains are cleaved to yield a somewhat smaller chain of 
-63 kDa. To identify the exact site of the plasmin 
cleavage, we phosphorylated only the V75 form of 
vitronectin by carrying out the reaction at pH 7.5. 
Under these conditions, V65 + 10 is not phosphorylated 
[17-19,211. The non-labeled V63 and the 32P-labeled VIZ 
(cf. Fig. 2) were identified, cut out and sequenced. On 
the basis of the amino acid residues positively identified 
(Table I), it was established that plasmin cleaves 
vitronectin at the Arg36’-Ser3”2 bond, reducing the 
molecular mass of the heavy chain of vitronectin to 
-63 kDa (Fig. 2). This cleavage clearly occurs in both 
v75 and v65 + IO, which yield (re.SpeCtiVely) V63 + 12 and 
V63 + IO f VZ (Fig. 3B). 
3.2. The plasmin cleavage of vitronectin attenuates 
the binding of PAI- 
Since the plasmin cleavage occurs within the heparin 
binding domain (positions 348-379) [31] and since this 
domain may probably be involved in the interaction of 
vitronectin with PAI- [5--8,101 we explored the effect 
of the plasmin cleavage of vitronectin on its binding on- 
to immobilized PAI-1. Using the enzyme immunoassay 
developed by Salonen et al. [6] we found that the 
plasmin cleavage of vitronectin significantly reduces its 
ability to bind PAI- (Fig. 3). This attenuation of bin- 
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Fig. 2. Determination of the plasmin cleavage site in vitronectin. Upperpanel: a vitronectin preparation obtained as described earlier [21] was selec- 
tively phosphorylated at %x3’s with PKA [17,19] and [Y~~P]ATP, allowing phosphorylation to take place in VZ only [18,19,21]. The Ser37s-labeled 
vitronectin was cleaved with plasmin (cf. legend to Fig. I) ascertaining cleavage completion by SDS/PAGE and autoradiography. After Western 
blotting onto an lmmobilon PVDF membrane, the N-terminus sequence of VIZ was determined by the procedure described elsewhere [19]. Lower 
pmel: sequence of a portion of vitronectin containing the positively charged cluster of basic amino acids (residues 348-381). This scheme illustrates 
the relationship between the site of phosphorylation of PKA [17,19] (Se?), the endogenous cleavage sile (Arg37’-Ala38”, previously assumed to 
be the site of plasmin cleavage [IO], the plasmin cleavage site (Arg 3e’-Ser3”2) established here on the basis of the N-terminus sequence of VIZ, and 
its vicinity to the C-terminus of the heparin binding site [3 1] (underlined). Note that the numbering of amino acid residues refers to the vitronectin 
sequence deduced by .lenne and Stanley [13]. 
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Table I 
Sequence of the plasmin cleavage products of vitronectin 
v63 VIZ 
Sequence determined Matching sequence in V,,* Sequence determined Matching sequence in V,,* 
Cycle Residue (yield**) Position Residue Cycle Residue (yield**) Position Kesidue _.__ 
I D (8) I 
: 
1 s (I.3 362 S 
2 Q (20) 2 2 Q (21) 363 
3 F (6) 3 E 3 R (3) 364 R’ 
4 S (5) 4 S 4 C (26) 365 G 
5 n.d. 5 C 5 _ *t* 366 H 
6 K (6) 6 K 6 S (7) 367 S 
7 C (11) 7 G 7 _ *#I* 368 R 
8 R _ *** 8 R 8 C (19) 369 G 
9 n.d. 9 C 9 _ *** 370 R 
IO T (4) IO T IO N (9) 371 
II F (3) II E II Q (12) 372 : 
I2 C (5) I2 G I2 N (2) 373 N 
I3 F (3) I3 F I3 S (6) 374 S 
I4 N (3) I4 N 
I5 V (4) I5 V 
*Following the sequence numbering deduced by Jenne and Stanley [I31 
**Number of pmols of amino acid-phenylthiohydantoin in derivative recovered 
***Yield too low for position identification 
n-d.. not detertnined (since the cysteines in k’,, were not pre-modified, they were not determined in this analysis). 
ding was observed in 4 such experiments. PAI- was ac- 
tivated by the 2 different procedures described in the 
literature [6,28] for the conversion of ‘latent’ PAI- to 
its ‘active’ form [3]. The attenuation was less extensive 
in some of the experiments, but in all 4 experiments the 
apparent affinity between V,, and PAI-I was at least 
IO-fold higher than the affinity between Vn’ and 
PAI-1. 
3.3. Stimulation of the plasmin cleavage by 
giyco5aminogiycans 
The plasmin cleavage of vitronectin was found to be 
stimulated by heparin (Fig. 4) or heparan-sulfate 
(results not shown). This stimulation occurred in both 
the V7s and the v65+ 10 forms of vitronectin. It was 
more pronounced in the case of \J65 + 10, where the rate 
of cleavage was very slow in the absence of the 
glycosaminoglycan (Fig. 4). This result would indicate 
that glycosaminoglycan-bound vitronectin (such as the 
vitronectin found in the vascular subendothelium [5-81) 
might well be preferentially cleaved by plasmin, con- 
fining this cleavage to the locus of the hemostatic event. 
It should be noted that this effect of glycosami- 
noglycans is in I& wi*r;i s;evious studies in our labor- 
atory on the hcparin-triggered conformational changes 
in vitronectin, which expose Ser378 and make it acces- 
sible to PKA phosphorylation [18,19]. 
The detailed mechanism through which the plasmin 
cleavage of vitronectin attenuates its PAI- binding re- 
mains to be established. In the case of V65 + 10 it may in- 
volve the loss of a peptide (Fig. 2), while in the case of 
both V7s and v65 + IO it may be the result of a conforma- 
tional change, since the cleavage occurs in a domain 
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which was previously shown to undergo such changes 
[18,19]. In a very recent publication, Seiffert and 
Loskutoff [32] have provided evidence that PAI- binds 
to the somatomedin I3 domain at the N-terminus of 
vitronectin. Since the latter has been previously propos- 
ed to interact with the glycosaminoglycan binding 
region of this protein [ 10,18,19], a cleavage-triggered 
conformational change in vitronectin may also be 
reflected in its somatomedin I3 domain. 
3.4. Concluciing remarks 
In order to control plasmin action, it is necessary first 
and foremost to arrest further production of plasmin 
from plasminogen (by the inhibition of plasminogen ac- 
tivator with PAI- [3,4]) and at the same time to inac- 
tivate the excess of already-formed plasmin (by 
cuz-plasmin inhibitor). The detailed molecular events 
which sense an excessive plasmin level and trigger the 
action of PAI- at the right time and place are not yet 
known. The simplest and most effective mechanism for 
that purpose would make use of plasmin itself as a 
signalling device. 
On the basis of the findings presented above regar- 
ding the site of the plasmin cleavage of vitronectin, its 
specificity, the way it is affected by glycosaminogly- 
cans, and the way it affects the binding of PAI- to 
vitronectin, we propose here a mechanism through 
which plasmin can arrest its own production by feed- 
back signal.ling (Scheme I). At the initial stage of 
fibrinolysis, the plasminogen activator converts plasmi- 
nogen to plasmin. This is made possible since PAI- is 
then anchored (trapped) by the vitronectin molecules 
immobilized in the extracellular matrix [33], pre- 
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SDS/PAGE 
Fig. 3. Effect of the plasmin cleavage of vitronectin on its binding onto irr,mobilized PAI-I. A vitronectin preparation (V,,) containing an approx- 
imately cquimolar concentration of V75 and V~S + 10 was cleaved with plasmin as described in Fig. I, allowing the V,S-+V~~ + 12 cleavage to proceed 
to completion (see panel 8). The native vitronectin (V,,) and its plasmin-clipped product (V,,‘) were compared with regard to their binding to im- 
mobilized activated PAI-I, determined by an enzyme immunoassay as described previously by Salonen et al. [6]. Each point in the graph represents 
the mean~:SEM of trip!icate determinations. The activation of PAL-I in this experiment was carried out by treatment with SDS [6]. The reduced 
binding of V,,’ was observed in 4 different experiments similar to that presented above. In 2 of these experiments PAI-I was activated by boiling 
(rather than by SDS treatment) as described by Katagiri et al. 1281. In all cases there was a distinct ( 2 IO-fold) difference in the half-maximal binding 
of V,, versus V,,‘. 
I I I 
0 3 6 9 12 t5 
Time (min.) 
Fig. 4. Effect of heparin on the rate of plasmin cleavage of V75 and 
Vhs + 10, A preparation of vitronectin containing approximately 
equimolar amounts of V7s and Vbs+ 10 was cleaved with plasmin 
(O.l%, w/v) in the presence (0,~) and in the absence (0,O) of a 
3-fold molar excess of hcparin. At the indicated times the reaction was 
arrested by boiling (3 min at 95°C) and the % cleavage was determin- 
ed by PKA phosphorylation, SDS/PAGE under reducing conditions, 
and autoradiography (as described in Fig. lC), followed by den- 
sitometric scanning of the 75 and 65 kDa bands. Note that the 63 kDa 
band is not phosphorylated (cleavage occurs at Arg3”’ and thus VM 
does not contain SerJ7s making it possible to follow the extent of 
cleavage of V~.S + 10 by monitoring the radioactivity of the 65 kDa band 
without interference from the adjacent 63 kDa band. 
sumably through glycosaminoglycans. This anchoring 
of PM-1 would locally deplete the inhibitor, preventing 
it from reaching and inhibiting the plasminogen ac- 
tivator. When plasmin levels become too high, the ex- 
cess plasmin clips preferentially the vitronectin 
molecules immobilized in the subendothelium. Con- 
Vn s t [PAI-l] - 
Thrombin 
Fibrinogen 
(4 
- Fibrin - Fibrin Degradation Products 
(i) 
t 
(6) 
Piasminogen lntiiie~ 
Scheme 1. The sequence of molecular events involved in fibrinolysis, 
showing the mechanism proposed here whereby plasmin can arrest its 
own production by feedbacking signalling, unleashing PAI-I from 
the immobilized vitronectin found in the extracellular matrix (e.g, the 
vascular subendothelium), which becomes exposed at the locus of a 
hemostatic event, PA, plasminogen activator; PAI-I, plasminogen 
activator inhibitor-i; V,,, vitronectin; V ,,I, plasmin-clipped vitronec- 
tin: (s), soluble; (i) insoluble; 0, stimulation; 0, inhibition. 
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sequently, the equilibrium between anchored PAI-I and 
the detached (mobile) PAI-I is displaced, thus 
unleashing PAI-I to reach and inhibit the plasminogen 
activator and arrest plasmin production. It should be 
emphasized that the above mechanism does not specify 
which species of mobile PAI- inhibits the plasminogen 
activator. It may be either free PAI-I or PAI-I attached 
to plasma vitronectin in a soluble, stable, and active 
complex [6]. The impairment of this control mechanism 
of plasmin production may have wider clinical implica- 
tions, in view of recent findings on the involvement of 
PAI- in angiogenesis [34], malignancy, and tumor in- 
vasion [I ,351. 
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